Donation from Dai-ichi Life Insurance Company and Protective Life Corporation will aid new disease-changing therapies in the ADDA pipeline.
New drugs to slow or even prevent Parkinson’s could be in human studies as early as 2015.
The UAB School of Medicine will lead in the establishment of a national research consortium focused on the discovery of new and better drug therapies to treat viral infections.
New marker predicts how resistant each patient’s brain cancer will be to chemotherapy.
UAB researchers have identified a set of experimental drugs called LRRK2 inhibitors that may go beyond symptom relief to directly counter the inflammation and nerve cell death at the root of Parkinson’s disease.